ED Drugs Linked to Lower Glaucoma Risk in Men After 3-Year Study
Men taking PDE-5 inhibitors like Viagra had up to 3% lower glaucoma risk, suggesting vascular eye benefits beyond sexual health.
Summary
A large study of over 23,000 men found that those taking PDE-5 inhibitors — drugs like sildenafil (Viagra) and tadalafil (Cialis) used for erectile dysfunction — had a modestly but significantly lower risk of developing glaucoma over three years. Researchers believe the benefit comes from improved blood flow to the optic nerve, not from changes in eye pressure. The absolute risk reduction was 1–3% for early glaucoma signs and about 1% for open-angle glaucoma. A separate finding from the same conference showed higher HDL cholesterol in women was linked to slightly lower risk of a severe form of age-related macular degeneration. Both findings point to vascular and lipid factors as underappreciated drivers of eye health and potential longevity-adjacent disease prevention.
Detailed Summary
Erectile dysfunction drugs may offer an unexpected benefit for eye health. A new study presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting found that men using PDE-5 inhibitors — including sildenafil, tadalafil, and vardenafil — had a statistically significant lower risk of glaucoma compared to men with erectile dysfunction who did not use these drugs.
The study drew on the TriNetX clinical database, covering 2005 to 2025, and matched 23,603 PDE-5 inhibitor users with 23,603 non-users, all men aged 40 or older with diagnosed erectile dysfunction. After one year, glaucoma suspect rates were 6.49% in users versus 9.73% in non-users. Open-angle glaucoma rates were 2.13% versus 3.22%. While the gap narrowed over three years, statistically significant differences persisted through the full follow-up period.
Researchers believe the mechanism is vascular rather than pressure-related. PDE-5 inhibitors enhance nitric oxide signaling, which improves blood flow to the optic nerve. Notably, these drugs do not lower intraocular pressure — the traditional target in glaucoma treatment — suggesting a distinct protective pathway that has been largely overlooked.
A second study from the same conference added to the vascular-eye-health picture. Women with HDL cholesterol above 60 mg/dL had a 9% relative risk reduction in neovascular age-related macular degeneration compared to women with low HDL. The effect was sex-specific and did not appear in men, hinting at hormonal or metabolic interactions worth investigating further.
Both findings are observational and require prospective trials to confirm causality. Still, for health-conscious adults, they reinforce the importance of vascular health — blood flow, lipid profiles, and endothelial function — as a lever for preserving vision and potentially extending healthy years. Men already prescribed PDE-5 inhibitors may be receiving ocular benefits they are unaware of.
Key Findings
- Men on PDE-5 inhibitors had up to 3% lower glaucoma suspect rates versus non-users over 3 years.
- Open-angle glaucoma rates were roughly 1% lower in PDE-5 inhibitor users, a statistically significant difference.
- The protective effect appears vascular — improved optic nerve blood flow — not reduced eye pressure.
- Women with HDL above 60 mg/dL had a 9% relative risk reduction in neovascular macular degeneration.
- HDL's protective eye effect was sex-specific; no significant benefit was seen in men.
Methodology
This is a meeting coverage news report from MedPage Today summarizing two poster presentations at the ARVO 2026 conference. The glaucoma study used a large propensity-matched retrospective cohort of 47,206 men from the TriNetX real-world database spanning 20 years, providing reasonable statistical power. Results are preliminary conference findings and have not yet been published in a peer-reviewed journal.
Study Limitations
Both studies are observational and cannot establish causation; confounding factors may not be fully controlled despite propensity matching. The glaucoma findings are from a conference poster and await peer-reviewed publication. The HDL-AMD association lost significance in time-to-event analysis, suggesting the effect size may be modest or unstable.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.